Rebalix
Logo iSharesiShares · sheet of 5 September 2026
ETF sheet · official issuer and register data

iShares MSCI World Health Care Sector Advanced UCITS ETF

WHCS · IE00BJ5JNZ06 · USD · domicile Ireland
Equity · Global · Health care · Large & mid capSFDR art. 8
Index tracked: MSCI World Health Care Advanced Select 20 35 Capped Index
TER
0.18%+ trans. 0.02%
Fund size
585 m EUR
Tracking difference
−0.05%3-year avg
🇮🇹 tax rate
26.00%white list 0.00%
Replication
Physical
Income
Distributingsemi-annual
Launch 17 Oct 2019 · costs from the KID as of 2 Sept 2026 · 112 securities held · 9 venues (ESMA register)

The fund’s objective — in the issuer’s words

From the Key Information Document (KID) · 4 Aug 2026
The Share Class is a share class of a Fund which aims to achieve a return on your investment, through a combination of capital growth and income on the Fund’s assets, which reflects the return of the MSCI World Health Care Advanced Select 20 35 Capped Index, the Fund’s benchmark index (Index). The Share Class, via the Fund, is passively managed and aims to invest so far as possible and practicable in the equity securities (e.g. shares) that make up the Index. The Index measures the performance of companies included in the MSCI World Health Care Index…

Performance since series start (in euro) — base 100

17 Oct 201931 Aug 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
202020212022202320242025202617389169
High 173 (19 Aug 2026) · low 89 (16 Mar 2020) · last 169. Past performance is not indicative of future results.

Returns in euro

1 year+19.3%
3 years+13.1%
5 years+21.2%
10 yearsseries too young
Since series start+69.2%

Risk · 1 / 3 / 5 years

Volatility (ann.)14.45%13.12%13.62%
Max drawdown−10.75%−18.57%−19.01%
Sharpe1.110.250.07
Sortino1.820.360.09
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · WHCS · IE00BJ5JNZ061
RebalixWHCS · IE00BJ5JNZ06 · sheet of 5 September 2026

Tracking difference — year by year

Fund minus index, complete calendar years · from issuer-declared series
YearFundIndexTD
2025+15.12%+15.14%−0.02%
2024−5.14%−5.10%−0.04%
2023+3.92%+4.02%−0.10%
2022−3.53%−3.40%−0.12%
2021+19.70%+19.80%−0.11%

Distributions · per share, in USD

Frequency: semi-annual · last 12 months: 0.10 USD (1.19% of NAV) · last ex-date 18 Jun 2026
YearPaymentsTotal (USD)Dividend yield
202610.06
202520.09+1.31%
202420.07+0.96%
202320.08+1.13%
202220.08+1.07%
Dividend yield: the year’s distributions over the share value (NAV) at the start of the year.

Holdings

Portfolio as declared by the issuer · 31 Aug 2026 · 112 securities · top-10 weight = 46.0%
Top holdingsWeight
ELI LILLY10.5%
JOHNSON & JOHNSON6.1%
ABBVIE5.5%
NOVARTIS AG5.2%
MERCK & CO INC3.7%
UNITEDHEALTH GROUP INC3.7%
ROCHE PS PAR AG3.6%
ASTRAZENECA PLC2.7%
GILEAD SCIENCES2.5%
AMGEN INC2.4%
Countries (% of fund)
United States70.4%Switzerland12.5%United Kingdom4.7%Japan3.7%France2.3%
Sectors (% of fund)
Health Care99.6%Cash and/or Derivatives0.4%

Listing venues

ESMA register (FIRDS) and official exchange lists
WHCS · Borsa Italiana (ETFplus)
CBUF · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 19 unmapped venues (MTF, RFQ, professional)

Official documents

Clickable links in the PDF
KID · www.blackrock.com/it/investitori-privati/literature/kiid/eu-priips-ish
Factsheet · www.ishares.com/gls-download/literature/fact-sheet/whcs-ishares-msci-w
Prospectus · www.blackrock.com/it/investitori-privati/literature/prospectus/ishares
The live sheet, always up to date
rebalix.com/en/etf/IE00BJ5JNZ06
Series, distributions, holdings and documents refresh daily.
Sheet produced on 5 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.

Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.

Rebalix · WHCS · IE00BJ5JNZ062